Bio-Diversity
By Fintan Walton
Pharma Deals Review: Vol 2008 Issue 101 (Table of Contents)
Published: 13 Oct-2008
DOI: 10.3833/pdr.v2008.i101.125 ISSN: 1756-7874
Section: Business Commentaries
Fulltext:
Abstract
Biotech CEOs often stress to their investors that they are focused on a specific technology or therapy area – the last thing they really want to be, but the sort of thing that investors like to hear. But there is a true dilemma here for biotech CEOs: should they persist with a focused development model, or spread risk by adopting a diverse project portfolio, or, at the very least, a dual business model?
Copyright: © IQVIA 2018
Last Issue PDF
RSS